OncoMatch/Clinical Trials/NCT07097363
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Is NCT07097363 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments for b-cell non-hodgkin lymphoma.
Treatment: Cyclophosphamide · Doxorubicin · Epcoritamab · Etoposide · Prednisone · Rituximab — This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody that can bind to two different antigens at the same time. Epcoritamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. The EPOCH-R is administrated as the standard of care treatment. This may help the immune system kill cancer cells. Giving epcoritamab with EPOCH-R may be safe, tolerable, and effective in treating patients with aggressive B-cell non-Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: MYC rearrangement
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Required: BCL2 rearrangement
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Required: BCL6 rearrangement
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Required: EBV positive
Epstein Barr virus (EBV) + DLBCL, NOS
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy for lymphoma
Exception: 1 prior cycle of chemoimmunotherapy may be allowed
Prior systemic treatment for lymphoma. 1 prior cycle of chemoimmunotherapy may be allowed.
Cannot have received: systemic therapy for indolent lymphoma
Prior systemic therapy for indolent lymphoma
Cannot have received: organ transplant
Prior organ transplantation
Lab requirements
Blood counts
ANC ≥ 1,000/μL except in cases of marrow infiltration by lymphoma; Platelets ≥ 75,000 / mcL except in cases of marrow infiltration by lymphoma or hypersplenism; Hemoglobin ≥ 8 g/dL except in cases of marrow infiltration by lymphoma without RBC transfusion within 14 days of first treatment
Kidney function
Measured or calculated creatinine clearance (GFR can also be used) ≥ 45 mL/min
Liver function
Serum total bilirubin ≤ 1.5 X ULN (≤ 3.0 x ULN for Gilbert disease); AST and ALT ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver involvement
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac MUGA scan or ECHO
ANC ≥ 1,000/μL except in cases of marrow infiltration by lymphoma; Platelets ≥ 75,000 / mcL except in cases of marrow infiltration by lymphoma or hypersplenism; Hemoglobin ≥ 8 g/dL except in cases of marrow infiltration by lymphoma without RBC transfusion within 14 days of first treatment; Measured or calculated creatinine clearance (GFR can also be used) ≥ 45 mL/min; Serum total bilirubin ≤ 1.5 X ULN (≤ 3.0 x ULN for Gilbert disease); AST and ALT ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver involvement; Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac MUGA scan or ECHO
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07097363 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy for lymphoma, systemic therapy for indolent lymphoma, organ transplant disqualifies patients from enrollment.
Does this trial require MYC?
Yes, MYC rearrangement is a required biomarker for enrollment.
Does this trial require BCL2?
Yes, BCL2 rearrangement is a required biomarker for enrollment.
Does this trial require BCL6?
Yes, BCL6 rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify